Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 June, 2024 12:23 IST
Cipla receives final approval for Arformoterol Tartrate Inhalation Solution
Source: IRIS | 23 Jun, 2021, 01.13PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

 Cipla, a leading drug maker, on June 23 announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).

Cipla's Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.'s Brovana.

Brovana is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

According to IQVIA (IMS Health), Brovana had US sales of approximately USD 438M for the 12-month period ending April 2021.

Shares of the company gained Rs 4.85, or 0.51%, to trade at  Rs 960.50.  The total volume of shares traded  was  617,667 at the BSE (11.47 a.m., Wednesday).



 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer